Aptissen SA
Mark Geißler has an extensive background in the pharmaceutical industry, with experience in sales, management, and business development. Currently, he holds multiple leadership roles at Aptissen SA and has previously held key positions at Aimmune Therapeutics, Fidia Pharma GmbH, Molteni Farmaceutici, Novartis, and Schwarz Pharma Deutschland GmbH. Mark has successfully led commercial teams, managed key accounts, and launched new products. His educational background includes a certificate in Business Administration - Marketing and Strategic Planning from FernUniversität in Hagen.
This person is not in any offices
Aptissen SA
Aptissen S.A. is a Swiss company specialized in the development and commercialization of biopolymer-based medical devices. Aptissen’s founders have developed for the past 25 years the best quality injectable products which meet both patients and doctors expectations: www.aptissen.com The company was founded in 2013 as a spin-off of ANTEIS, and is based in Geneva area, Switzerland. It today distributes its products through a worldwide international distributors' network among more than 90 countries including Europe, South America, Canada, Middle East and Asia. Aptissen's team revolutionized the viscosupplement market with Synolis VA and his patented formulation which combines Hyaluronic Acid and Sorbitol. Synolis VA provides rapid mobility recovery, fast long lasting pain relief associated with excellent safety: www.synolis.com We place the patient benefit at the center of our mission to develop innovative injectable solutions based on hyaluronic acid to provide fast pain relief.